AVO:LSE-Advanced Oncotherapy plc (GBX)

COMMON STOCK | Medical Devices | LSE

Last Closing Price

GBX 34.00

Change

0.00 (0.00)%

Market Cap

GBX 0.12B

Volume

0.06M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SN:LSE Smith & Nephew plc

-99.00 (-6.33%)

GBX13.75B 42.26 17.06
CREO:LSE Creo Medical Limited

+7.00 (+3.54%)

GBX0.32B N/A N/A
MGP:LSE Medica Group Plc

N/A

GBX0.21B 144.17 38.59
POLX:LSE Polarean Imaging plc

+1.00 (+1.15%)

GBX0.18B N/A N/A
IDH:LSE Immunodiagnostic Systems Holdi..

N/A

GBX0.11B 290.77 22.62
IHC:LSE Inspiration Healthcare Group p..

+1.50 (+1.23%)

GBX0.08B 23.82 16.21
KMK:LSE Kromek Group plc

+1.85 (+9.97%)

GBX0.08B N/A 19.23
BELL:LSE Belluscura Plc

N/A

GBX0.08B N/A N/A
MED:LSE Intelligent Ultrasound Group p..

N/A

GBX0.04B N/A N/A
IUG:LSE Intelligent Ultrasound Group p..

N/A

GBX0.04B N/A N/A

ETFs Containing AVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.56% 17% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.56% 17% F 16% F
Trailing 12 Months  
Capital Gain 36.00% 70% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.00% 70% C- 64% D
Trailing 5 Years  
Capital Gain -72.13% 25% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.13% 25% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 9.56% 80% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.56% 80% B- 56% F
Risk Return Profile  
Volatility (Standard Deviation) 72.25% 10% F 22% F
Risk Adjusted Return 13.23% 50% F 35% F
Market Capitalization 0.12B 71% C- 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.54 69% D+ 36% F
Price / Cash Flow Ratio -5.84 50% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.11% 21% F 9% F
Return on Invested Capital -34.00% 29% F 10% F
Return on Assets -10.87% 43% F 14% F
Debt to Equity Ratio 18.71% 63% D 60% D-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.88 38% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector